Skip to main content
. 2019 Mar 4;6:3. doi: 10.1186/s40673-019-0097-2

Fig. 2.

Fig. 2

Frequency analysis of P300 abnormalities in SCA2 patients and preclinical carriers and controls (a) and ROC analysis of P300 peak latency abnormalities in SCA2 patients (b). Blue trace: Cz; Red trace: Pz